By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > Bisphosphonate > Alendronate

Alendronate

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|596 words

What is Alendronate?

Alendronate is a prescription medication belonging to a class of drugs called bisphosphonates. It is primarily used to treat and prevent osteoporosis, particularly in postmenopausal women and men at risk for bone fractures. The medication works by slowing bone breakdown and helping to maintain bone density and strength.

Uses

Alendronate is prescribed for several bone-related conditions:

  • Postmenopausal osteoporosis treatment and prevention: Reduces fracture risk by increasing bone mineral density in the spine and hips
  • Male osteoporosis: Treats osteoporosis in men who have low bone density or are at high risk for fractures
  • Glucocorticoid-induced osteoporosis: Prevents and treats bone loss in patients taking corticosteroid medications long-term
  • Paget’s disease: Helps normalize bone turnover in this condition where bones become enlarged and weakened
  • Prevention in high-risk patients: Used in individuals with risk factors for osteoporosis before significant bone loss occurs

How it works

Alendronate inhibits osteoclasts, the cells responsible for breaking down bone tissue. By reducing bone resorption while allowing bone formation to continue, the medication helps restore the balance between bone breakdown and rebuilding. This process gradually increases bone density and reduces the risk of fractures over time.

Side effects

Common side effects include:

Submit Your Paper
GMJ_Submit_Banner
  • Stomach pain and digestive upset
  • Heartburn and acid reflux
  • Nausea
  • Constipation or diarrhea
  • Muscle or joint pain
  • Headache
  • Dizziness
  • Metallic taste in mouth

Serious side effects requiring immediate medical attention:

  • Severe chest pain or difficulty swallowing
  • Jaw pain, swelling, or loose teeth (potential osteonecrosis)
  • Unusual thigh, hip, or groin pain (atypical fractures)
  • Severe bone, joint, or muscle pain
  • Signs of low blood calcium (muscle spasms, numbness, tingling)

Warnings and precautions

  • Esophageal problems: Patients with esophageal disorders, difficulty swallowing, or inability to stand upright for 30 minutes should not use alendronate due to risk of severe esophageal irritation
  • Kidney function: Not recommended for patients with severe kidney disease (creatinine clearance less than 35 mL/min)
  • Low blood calcium: Hypocalcemia must be corrected before starting treatment, and patients should ensure adequate calcium and vitamin D intake
  • Pregnancy and breastfeeding: Not recommended during pregnancy or breastfeeding due to potential effects on fetal bone development
  • Dental procedures: Inform dentists about alendronate use, as invasive dental work may increase risk of jaw problems

Interactions

  • Calcium supplements and antacids: Significantly reduce alendronate absorption; must be taken at least 30 minutes after alendronate
  • Iron supplements: Can decrease alendronate effectiveness when taken together
  • Aspirin and NSAIDs: May increase risk of stomach irritation and ulcers
  • Proton pump inhibitors: Long-term use may reduce alendronate effectiveness
  • Aminoglycosides: Combined use may increase risk of low blood calcium
  • Coffee, tea, and juice: Can interfere with absorption; take alendronate with plain water only
  • Magnesium-containing products: Reduce drug absorption and should be separated by several hours
  • Multivitamins: May contain minerals that interfere with absorption

Check interactions with the GMJ Interaction Checker

Dosage

For osteoporosis treatment, the typical adult dose is 70 mg taken once weekly or 10 mg taken once daily. For prevention of osteoporosis, 35 mg once weekly or 5 mg once daily is commonly prescribed. For Paget’s disease, 40 mg daily for six months is the standard regimen. Alendronate must be taken first thing in the morning with a full glass of plain water, at least 30 minutes before any food, beverages, or other medications. Patients must remain upright for at least 30 minutes after taking the medication. Dosage should always be determined and monitored by a healthcare provider based on individual patient factors and response to treatment.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Alendronate." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/alendronate/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
UK Health and Safety Authorities Issue Joint Warning on Asbestos in Consumer Products

UK regulatory authorities issue joint warning on asbestos contamination in imported consumer…

UK Releases Rabies Post-Exposure Risk Assessment Tool for Clinical Practice

The UK Department of Health and Social Care has published a standardised…

UK Sets Minimum Age of 11 for Puberty Blocker Clinical Trial in Gender-Questioning Children

The UK has set a minimum age of 11 years for children…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Risedronate

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up